Science Corp raises $400M Series D to scale PRIMA retinal implant in Europe and US

emmanuelvivier · x · 2026-11-18

Science Corporation announced a $400 million Series D, bringing total capital since its 2021 founding to over $900 million. The funding accelerates the European rollout of its PRIMA retinal implant, prepares a US launch, expands R&D and manufacturing, and funds its biohybrid neural-interface program.

Investors include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech. PRIMA received CE mark under the EU MDR and launched commercially across 30 European countries in July 2026; its 36-month trial showed a mean 29-letter vision improvement with no new safety signal after month 12.

Original post →

More from Venture

Venture channel →